Introduction {#s1}
============

In daily clinical practice, low molecular weight heparins (LMWH) and unfractionated heparin (UFH) are the most commonly prescribed anticoagulant drugs for the treatment of acute thrombotic conditions, such as venous thromboembolism (VTE) and acute coronary syndromes (ACS).

LMWH have some advantages over UFH, including higher bioavailability and a more predictable anticoagulant effect. These properties allow the use of LMWH at weight-adjusted doses in most patients, without the need for laboratory monitoring. On the other hand, although treatment with UFH needs laboratory monitoring with Activated Partial Thromboplastin Time (aPTT), because its anticoagulant effect is unpredictable, it has the advantage that bleeding complications can be more easily managed, because UFH has a shorter half-life than LMWH, and can be effectively antagonized by protamine [@pone.0044553-Kearon1].

The antithrombotic efficacy of LMWH and UFH in the treatment of VTE and ACS has been evaluated in many randomized clinical trials and analyzed in several meta-analyses. Treatment of VTE with LMWHs is associated with similar or lower rates of recurrences and death as compared to treatment with UFH [@pone.0044553-Quinlan1]; [@pone.0044553-Erkens1]. However, there is no evidence that LMWH are more effective than UFH in patients with ACS [@pone.0044553-Harrington1].

Minimizing the bleeding risk in patients treated with anticoagulants is of utmost clinical relevance, considering that major bleeding, anemia and blood transfusion are powerful and independent predictors of morbidity and mortality in patients with VTE or ACS on treatment with antithrombotic drugs [@pone.0044553-Sabatine1]--[@pone.0044553-Jimenez1]. To date, the systematic reviews comparing LMWH and UFH, focused on drug efficacy as primary end point and considered the incidence of bleeding a secondary end point. This choice could have affected the selection of studies to be included in the analysis, since some studies reporting haemorrhagic events could have been excluded due to the absence of the primary end point considered as inclusion criteria in those meta-analysis.

It has not been established yet whether the incidence of bleeding complications differs between LMWH and UFH.

Aim of our study was to perform a systematic review of randomized clinical trials to compare the incidence of major bleeding associated with the use of subcutaneous LMWH and intravenous UFH for treatment of acute VTE or ACS.

Materials and Methods {#s2}
=====================

Data Sources and Searches {#s2a}
-------------------------

We attempted to identify all relevant published randomized controlled trials (RCT) that compared fixed-dose subcutaneous LMWH with adjusted-dose intravenous UFH in the initial treatment of thrombotic episodes. We searched MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials, using the search terms "randomized controlled trials" and "heparin" in combination with generic and trade names of individual preparations of LMWH. The search was completed in May 2010. We manually searched the references of retrieved publications to look for additional studies. No language restrictions were applied. Two investigators (EC, AMR) independently evaluated the studies for inclusion, and disagreements were resolved by discussion.

Study Selection {#s2b}
---------------

In order to be included in this systematic review, published studies had to meet the following criteria: 1) study design: randomized controlled trial; 2) intervention: comparison of subcutaneous weight-adjusted, fixed-dose LMWH with adjusted doses (based on APTT values) intravenous UFH, for the initial treatment of acute thrombotic episodes; 3) availability of outcome data on the incidence of major bleeding. We accepted the definitions of major bleeding that were chosen in each individual trial. Dose-finding studies were excluded. Studies with no events in both LMWH and UFH arms were included in the descriptive analysis, but excluded from the meta-analysis, because calculation of the odds ratio (OR) was not feasible.

Pre-defined subgroup analyses were performed on the basis of the type of disease that was treated (VTE vs ACS), the doses of LMWH that were administered, the number of daily administrations of LMWH (one or two) and the type of LMWH used.

Quality Assessment {#s2c}
------------------

In order to evaluate the quality of the included studies, we used the study-quality criteria of Jadad, which take into account proper randomization, allocation of patients and blinding [@pone.0044553-Jadad1].

Data Extraction {#s2d}
---------------

Two investigators (EC, AMR) independently extracted the data on study design, study quality, incidence of major bleeding, patients' characteristics, type, dose and number of daily administrations of LMWH, co-treatments, study end points and efficacy outcome. The data extracted for each trial were confirmed by consensus between the reviewers.

Data Analysis {#s2e}
-------------

For each primary study that was included in the meta-analysis, a two-by-two table was constructed and the OR, with their 95% confidence intervals (CI), were calculated to estimate the risk of major bleeding in patients treated with LMWH compared to patients treated with UFH.

Pooled OR and 95% CI were calculated using the random effects model [@pone.0044553-DerSimonian1]. The homogeneity of the estimates of OR among studies was evaluated using the chi-square statistic test. Given the known difference of clinical settings of primary studies included in our meta-analysis (clinical heterogeneity), random effects analysis was performed for all studies, irrespective of the statistical significance of the heterogeneity chi-square test.

All analyses were performed using STATA 11.0 software [@pone.0044553-Stata1].

Results {#s3}
=======

Study Selection {#s3a}
---------------

[Figure 1](#pone-0044553-g001){ref-type="fig"} shows the process of study selection. We identified 6513 articles (1498 from Medline, 3205 from Embase, 1810 from the Cochrane Library). Of these, 1515 studies were duplicates, which were therefore eliminated, leaving 4998 articles for consideration. After the exclusion of irrelevant studies, which were identified by reviewing the titles and abstracts of all retrieved articles, 112 publications remained for analysis. We could not obtain the full publication of 19 studies after searching in the British Library and writing to the authors. Fifty-four of the remaining 93 articles were subsequently excluded, based on a more detailed evaluation of the full publications ([Fig. 1](#pone-0044553-g001){ref-type="fig"}). No additional studies were identified by reviewing the references from the original studies and other meta-analyses. One study, which operated a double randomization was considered as two data sets [@pone.0044553-Kim1]. Thus, 37 studies were included in the descriptive analysis [@pone.0044553-Kim1]--[@pone.0044553-Aiach1]. In 10 of them, no bleeding events were observed in any treatment group: therefore, 27 studies were included in the meta-analysis [@pone.0044553-Riess1]--[@pone.0044553-Zhang1]; [@pone.0044553-1]--[@pone.0044553-Kirchmaier1]; [@pone.0044553-Aiach1].

![Study selection progression.](pone.0044553.g001){#pone-0044553-g001}

[Table 1](#pone-0044553-t001){ref-type="table"} describes the characteristics of the included studies. Thirty-four studies were published in English, one in French and two in Spanish, in journals of Internal Medicine, Cardiology, Hematology, or, less frequently, Angiology and Pneumology. The years of publication ranged between 1989 and 2006. Twenty-six studies enrolled patients with VTE, 11 studies enrolled patients with ACS (STEMI, NSTEMI, unstable angina). Nine different types of LMWH were used: the most commonly used one was enoxaparin. In all studies, the dose of intravenous UFH was titrated to maintain the APTT ratio between 1.5 and 2.5. The daily doses of subcutaneous LMWH ranged between 90 and 300 anti-Xa U/kg (mean 195 U/kg), in one or two daily administrations (9 and 28 studies respectively); one study allowed both the once daily and the twice daily administration [@pone.0044553-Breddin1]. Treatments lasted between 2 and 28 days (mean, 8 days). Concomitant medications for patients with ACS included Aspirin, Aspirin plus a thienopiridine, Aspirin plus a GPIIb-IIIa inhibitor, or Aspirin plus a thrombolytic agent. Most studies used the TIMI criteria to define major bleeding [@pone.0044553-Antman1].

10.1371/journal.pone.0044553.t001

###### Characteristics of included studies.

![](pone.0044553.t001){#pone-0044553-t001-1}

                                                   Clinical indication   Patients n.   Major bleeding n. (%)   Mean age (years)   Type and daily dosage of LMWH                             Cotreatments                             
  ----------------------------------------------- --------------------- ------------- ----------------------- ------------------ ------------------------------- ------------------------------------------------------------------- ------------------------------
  Riess H et al. 2003                                      VTE              LMWH                627                6 (1.0)                     61                                     Certoparin, 8000 IU, bid                                    None
                                                                             UFH                593                7 (1.3)                                                                                                           
  Decousus et al. 1998                                     VTE              LMWH                195                7 (3.6)                     72                                    Enoxaparin, 100 IU/Kg, bid                                   None
                                                                             UFH                205                8 (3.9)                                                                                                           
  Columbus investigators 1997                              VTE              LMWH                510                10 (2.0)                    60                                   Reviparin, 3500--6300 IU, bid                                 None
                                                                             UFH                511                8 (1.6)                                                                                                           
  Zhang Wang et al. 2006                                   ACS              LMWH                96                 1 (1.0)                     66                                     Parnaparin, 4250 IU, bid                                  ASA, UK
                                                                             UFH                90                 3 (3.1)                                                                                                           
  Hull et al. 1992                                         VTE              LMWH                213                1 (0.5)                   No data                                  Tinzaparin, 175 IU/Kg, qd                                   None
                                                                             UFH                219                11 (5.0)                                                                                                          
  Collaborative European Multicentre Study 1991            VTE              LMWH                85                 2 (2.4)                   No data                              Nadroparin, 12500--17500 IU, bid                                None
                                                                             UFH                81                 4 (4.9)                                                                                                           
  Campos et a. 2002                                        ACS              LMWH                107                1 (0.9)                     60                                     Enoxaparin, 80 IU/Kg, bid                                   ASA
                                                                             UFH                96                 9 (9.4)                                                                                                           
  Goldhaber et al. 1998                                    VTE              LMWH                41                 1 (2.4)                     54                                      Ardeparin, 130 /Kg, bid                                    None
                                                                             UFH                39                 1 (2.6)                                                                                                           
  Simonneau et al. 1997                                    VTE              LMWH                304                3 (1.0)                     67                                     Tinzaparin, 175 IU/Kg, qd                                   None
                                                                             UFH                308                5 (1.6)                                                                                                           
  PRIME CARE Study Investigators Group 2005                ACS              LMWH                451                2 (0.4)                     57                                      Parnaparin, 6400 IU, qd                                    ASA
                                                                             UFH                446                2 (0.4)                                                                                                           
  Goodman et al. 2003                                      ACS              LMWH                380                8 (2.1)                     64                                    Enoxaparin, 100 IU/Kg, bid                                 ASA, EPF
                                                                             UFH                366                20 (5.5)                                                                                                          
  Kakkar et al. 2003                                       VTE              LMWH                126                 0 (0)                    No data                                  Bemiparin, 115 IU/Kg, qd                                    None
                                                                             UFH                126                1 (1.0)                                                                                                           
  Prandoni et al. 1992                                     VTE              LMWH                85                 1 (1.2)                   No data                              Nadroparin, 12500--17500 IU, bid                                None
                                                                             UFH                85                 3 (3.5)                                                                                                           
  Levine et al. 1996                                       VTE              LMWH                247                5 (2.0)                     58                                    Enoxaparin, 100 IU/Kg, bid                                   None
                                                                             UFH                253                3 (1.2)                                                                                                           
  Gurfinkel et al. 1995                                    ACS              LMWH                68                  0 (0)                      63                                    Nadroparin, 214 IU/Kg, bid                                   ASA
                                                                             UFH                70                 2 (2.9)                                                                                                           
  Harenberg et al. 2000                                    VTE              LMWH                265                4 (1.5)                     62                                     Certoparin, 8000 IU, bid                                    None
                                                                             UFH                273                11 (4.0)                                                                                                          
  Cohen et al. 2002                                        ACS              LMWH                315                4 (1.3)                     64                                    Enoxaparin, 100 IU/Kg, bid                                 ASA, TFB
                                                                             UFH                210                3 (1.4)                                                                                                           
  Blazing et al. 2004                                      ACS              LMWH               2026                18 (0.9)                    61                                    Enoxaparin, 100 IU/Kg, bid                                 ASA, TFB
                                                                             UFH               1961                8 (0.4)                                                                                                           
  Breddin et al. 2001                                      VTE              LMWH                762                2 (0.3)                     59                               Reviparin, 7000--12600 IU, qd or bid                              None
                                                                             UFH                375                2 (0.6)                                                                                                           
  Perez de Llano et al. 2003                               VTE              LMWH                29                 1 (3.4)                   No data                                 Enoxaparin, 100 IU/Kg, bid                                   None
                                                                             UFH                21                  0 (0)                                                                                                            
  Fiessinger et al. 1996                                   VTE              LMWH                120                 0 (0)                      61                     Dalteparin, subcutaneous bolus 5000 IU, then 200 IU/kg qd                   None
                                                                             UFH                133                2 (1.5)                                                                                                           
  Harenberg et al. 1990                                    VTE              LMWH                24                 3 (12.5)                    61                                    Certoparin, 150 IU/Kg, bid                                   None
                                                                             UFH                26                 3 (11.5)                                                                                                          
  Luomanmaki et al. 1996                                   VTE              LMWH                117                 0 (0)                      59                     Dalteparin, subcutaneous bolus 5000 IU, then 200 IU/kg qd                   None
                                                                             UFH                131                1 (0.8)                                                                                                           
  Koopman et al. 1996                                      VTE              LMWH                202                1 (0.5)                     60                                  Nadroparin, 8200--18400 IU, bid                                None
                                                                             UFH                198                2 (1.0)                                                                                                           
  Cohen et al. 1997                                        ACS              LMWH               1607               102 (6.3)                    63                                    Enoxaparin, 100 IU/Kg, bid                                   ASA
                                                                             UFH               1564               107 (6.8)                                                                                                          
  SYNERGY Trial Investigators 2004                         ACS              LMWH               4993               453 (9.1)                    68                                    Enoxaparin, 100 IU/Kg, bid                       ASA clopidogrel/antiIIb/IIIa
                                                                             UFH               4985               379 (7.6)                                                                                                          
  Kirchmaier et al. 1998                                   VTE              LMWH                128                1 (0.8)                     61                                     Certoparin, 8000 IU, bid                                    None
                                                                             UFH                131                4 (3.1)                                                                                                           
  Belcaro et al. 1999                                      VTE              LMWH                98                  0 (0)                      53                                    Nadroparin, 100 IU/Kg, bid                                   None
                                                                             UFH                97                  0 (0)                                                                                                            
  Malhotra et al. 2001                                     ACS              LMWH                51                  0 (0)                      60                                    Enoxaparin, 100 IU/Kg, bid                                   ASA
                                                                             UFH                42                  0 (0)                                                                                                            
  Moreno Palomares et al. 2001                             VTE              LMWH                17                  0 (0)                      67                                     Dalteparin, 200 IU/Kg qd                                    None
                                                                             UFH                15                  0 (0)                                                                                                            
  Simonneau et al. 1993                                    VTE              LMWH                67                  0 (0)                      62                                    Enoxaparin, 100 IU/Kg, bid                                   None
                                                                             UFH                67                  0 (0)                                                                                                            
  Meyer et al. 1995                                        VTE              LMWH                29                  0 (0)                      61                                    Dalteparin, 120 IU/kg, bid                                   None
                                                                             UFH                31                  0 (0)                                                                                                            
  Findik et al. 2002                                       VTE              LMWH                29                  0 (0)                      50                                     Enoxaparin, 100 IU/Kg bid                                   None
                                                                             UFH                30                  0 (0)                                                                                                            
  Lindmarker et al. 1994                                   VTE              LMWH                101                 0 (0)                      61                                     Dalteparin, 200 IU/Kg, qd                                   None
                                                                             UFH                103                 0 (0)                                                                                                            
  Stricker et al. 1999                                     VTE              LMWH                 9                  0 (0)                      66                                     Nadroparin, 185 IU/Kg, qd                                   None
                                                                             UFH                11                   0 (0                                                                                                            
  Kim et al. (a) 2005                                      ACS              LMWH                40                  0 (0)                      63                                    Dalteparin, 120 IU/Kg, bid                             ASA, Clopidogrel
                                                                             UFH                40                  0 (0)                                                                                                            
  Kim et al. (b) 2005                                      ACS              LMWH                40                  0 (0)                      59                                    Dalteparin, 120 IU/Kg, bid                          ASA, Clopidogrel, TFB
                                                                             UFH                40                  0 (0)                                                                                                            
  Aiach et al. 1989                                        VTE              LMWH                31                  0 (0)                      62                 Dalteparin, 100 IU/Kg bid, then in function of antifactor Xa, bid               None
                                                                             UFH                30                  0 (0)                                                                                                            

**n**: numbers; **LMWH**: low molecular weight heparin; **UFH**: unfractioned heparin; **VTE**: venous thromboembolism; **ACS**: acute coronary syndrome; **qd**: once daily; **bid**: twice daily; **tid**: three times a day; **UK**: urochinasi; **TFB**: tirofiban; **EPF**: eptifibatide; **antiIIb/IIIa**: GPIIb/IIIa inhibitors; **ASA**: acetylsalicylic acid.

A total of 28,637 patients had been enrolled in the studies, 14,635 of whom were treated with LMWH and 14,002 with UFH. The mean number of patients enrolled in each trial was 754 (range 20--9,978 ), their mean age was 62 y (range 49--73), and 63% (range 31--83%) were men.

The aim of the majority of the studies was to evaluate combined end-points; less frequently, a single clinical end-point or an instrumental measure were evaluated. Major bleeding ranged from 0 to 12.5%, (mean, 4.4%) in patients treated with LMWH and from 0 to 11.5% (mean, 4.4%) in patients treated with UFH. The mean incidence of bleeding events were lower in VTE (1.1% with LMWH and 1.9% with UFH), compared to ACS (5.8% with LMWH and 5.4% with UFH). Considering the efficacy end-points, 15 studies showed that LMWH were superior to UFH [@pone.0044553-Riess1]; [@pone.0044553-Zhang1]; [@pone.0044553-1]--[@pone.0044553-Goldhaber1]; [@pone.0044553-2]--[@pone.0044553-Kakkar1]; [@pone.0044553-Gurfinkel1]; [@pone.0044553-Harenberg1]; [@pone.0044553-deLemos1]; [@pone.0044553-Breddin1]; [@pone.0044553-Cohen2]; [@pone.0044553-Malhotra1]; [@pone.0044553-Simonneau2], 1 study showed that UFH was superior to LMWH [@pone.0044553-Stricker1], while the remaining 21 showed that there was no statistically significant difference between the two treatments [@pone.0044553-Kim1]; [@pone.0044553-Decousus1]; [@pone.0044553-TheColumbus1]; [@pone.0044553-Hull1]; [@pone.0044553-Simonneau1]; [@pone.0044553-Prandoni1]; [@pone.0044553-Levine1]; [@pone.0044553-Cohen1]; [@pone.0044553-PerezdeLlano1]--[@pone.0044553-Koopman1]; [@pone.0044553-Ferguson1]--[@pone.0044553-Belcaro1]; [@pone.0044553-MorenoPalomares1]; [@pone.0044553-Meyer1]--[@pone.0044553-Lindmarker1]; [@pone.0044553-Aiach1].

Assessment of Study Quality {#s3b}
---------------------------

Based on the study-quality criteria of Jadad [@pone.0044553-Jadad1], 3 studies scored 1 point, 17 scored 2 points, 14 scored 3 points, 1 scored 4 points and 2 scored 5 points. Lack of blindness was the most common flaw in the studies with a low Jadad score.

Data Synthesis {#s3c}
--------------

Pooled estimates of ORs for major bleeding showed a non-statistically significant trend in favor of LMWH compared to UFH (OR = 0.79, 95% CI: 0.60--1.04, p = 0.091; n = 27 primary studies) ([Figure 2](#pone-0044553-g002){ref-type="fig"}).

![Pooled estimates of OR for major bleedings of LMWH versus UFH in all patients.](pone.0044553.g002){#pone-0044553-g002}

When the analysis was limited to trials that enrolled patients with VTE, pooled estimates of OR was in favor of LMWH (OR = 0.68, 95% CI: 0.47--1.00, p = 0.05) ([figure 3](#pone-0044553-g003){ref-type="fig"}).

![Pooled estimates of OR for major bleedings of LMWH versus UFH in VTE patients.](pone.0044553.g003){#pone-0044553-g003}

Study Characteristics {#s3d}
---------------------

In contrast, when the analysis was limited to trials that enrolled patients with ACS, no statistically significant differences between LMWH and UFH were found (OR = 0.87, 95% CI: 0.59--1.29; p = 0.493) ([figure 4](#pone-0044553-g004){ref-type="fig"}).

![Pooled estimates of OR for major bleedings of LMWH versus UFH in ACS patients.](pone.0044553.g004){#pone-0044553-g004}

Once daily LMWH was significantly safer than UFH, (OR = 0.39, 95% CI: 0.16--0.95, p = 0.039), while, for twice daily LMWH, no statistical difference was observed compared to UFH (OR = 0.86, 95% CI: 0.65--1.14, p = 0.296) ([figure S1](#pone.0044553.s001){ref-type="supplementary-material"}). When the analysis was limited to the subgroup of VTE trials, once daily LMWH was significantly safer than UFH (OR = 0.31, 95% CI: 0.12--0.84), while no significant differences were found when considering the other subgroups (VTE twice, ACS once and ACS twice) ([figure S2](#pone.0044553.s002){ref-type="supplementary-material"}).

The exclusion of studies in which LMWH was under-dosed (less than 75% of the recommended daily dose) or overdosed (more than 125% of the recommended dose) did not substantially change the results (OR = 0.79, CI 95% 0.58--1.06, p = 0.121) ([figure S3](#pone.0044553.s003){ref-type="supplementary-material"}).

No statistically significant differences among different LMWH were observed ([figure S4](#pone.0044553.s004){ref-type="supplementary-material"}).

The results did not change, after Exclusion of the low quality studies (Jadad score \<3) from the analysis (OR = 0.88, 95% CI: 0.67--1.15, p = 0.342) ([figure S5](#pone.0044553.s005){ref-type="supplementary-material"}).

Based on our a priori defined protocol, we excluded dose-finding studies [@pone.0044553-Correia1]--[@pone.0044553-Merli1], which had been included in other revisions. In particular, in the VTE setting, the study by Merli et al., which used two different LMWH doses, compared to a single UFH group, was excluded despite the large number of patients enrolled. For the sake of completeness, we repeated our analysis including the dose-finding trials and the results did not change ([figure S6](#pone.0044553.s006){ref-type="supplementary-material"}).

Discussion {#s4}
==========

Our systematic review shows a trend toward a non-statistically significant lower incidence of major bleeding with LMWH compared to UFH (OR 0.79), in the treatment of acute thrombotic events, such as VTE and ACS. When we analyzed separately the RCT that enrolled VTE patients and those enrolling ACS patients, the reduction in the bleeding risk associated with LMWH (OR = 0.68, p = 0.05) reached statistical significance for VTE. Some reasons might explain the absence of significant difference in bleeding between LMWH and UFH in ACS patients: i) many ACS patients underwent invasive procedures (coronary angiography and PCI), ii) ACS patients were often in co-treatment with antiplatelet agents; iii) LMWH patients are likely to be more often in the therapeutic range compared to dose adjusted UFH.

Somewhat unexpectedly, the incidence of bleeding complications was significantly lower with once daily administrations of LMWH, compared to twice daily administrations, the total daily doses being similar in the two treatment regimens ([figure S1](#pone.0044553.s001){ref-type="supplementary-material"}). Although we have not a clear explanation of these results, it could be speculated that bleeding correlates better with the trough drug concentrations (lower in once a day than in twice a day administrations) than with peak concentrations (higher in daily administration).

Anyway, our findings raise the possibility that dosing regimens can be important determinants for bleeding complications. Further studies should clarify this topic.

The use of LMWH and UFH for treatment of VTE and ACS has been evaluated in previous systematic reviews and meta-analyses, which were focused on their antithrombotic efficacy as primary end-point. However, in consideration of the negative impact on mortality and adverse cardiovascular events associated with major bleeding [@pone.0044553-Sabatine1]--[@pone.0044553-Jimenez1], it is also important to establish which treatment is safer, in terms of incidence of bleeding complications.

As far as treatment of VTE is concerned, only the meta-analysis of Lim et al on LMWH-associated bleeding is available to date [@pone.0044553-Lim1], which demonstrated a higher incidence of bleeding complications in patients with renal failure, without comparing LMWH with UFH. Information on the difference in bleeding complications between LMWH and UH is retrievable from two other meta-analyses, which were mainly focused on evaluating the differences in efficacy between the two treatments [@pone.0044553-Quinlan1]; [@pone.0044553-Erkens1]. Quinlan et at. reported a non-statistically significant trend toward lower frequency of major bleeding associated with LMWH, compared to UFH (1.4% vs 2.3%, OR 0.67, 95% CI 0.36--1.27), in patients with non-massive pulmonary embolism [@pone.0044553-Quinlan1]. In the Systematic Review of the Cochrane Collaboration on VTE [@pone.0044553-Erkens1], LMWH were shown to be significantly safer than UFH (incidence of major bleeding, 1% vs 2.1%, OR 0.57; 95% CI 0.39--0.83). While, at a first glance, our review seems to be very similar to the Cochrane review, we think that they are basically different. The recently published Cochrane meta-analysis focused on the comparison between LMWH and unfractionated heparin (UFH in terms of their efficacy for the initial treatment of venous thromboembolism (VTE). In our manuscript we have chosen the safety of these drugs for the initial treatment of acute thrombotic events as primary end point. As a consequence, in our review all the studies reporting haemorrhagic events, irrespective of the efficacy endpoint that was reported, have been included. As a consequence, compared to the Cochrane meta-analysis, 9 additional studies were included in our descriptive analysis [@pone.0044553-Goldhaber1]; [@pone.0044553-Kakkar1]; [@pone.0044553-Breddin1]; [@pone.0044553-PerezdeLlano1]; [@pone.0044553-Harenberg2]; [@pone.0044553-MorenoPalomares1]; [@pone.0044553-Meyer1]; [@pone.0044553-Stricker1]; [@pone.0044553-Aiach1], 6 of which were also included in our meta-analysis [@pone.0044553-PerezdeLlano1]; [@pone.0044553-Harenberg2]; [@pone.0044553-MorenoPalomares1]; [@pone.0044553-Meyer1]; [@pone.0044553-Stricker1]; [@pone.0044553-Aiach1]. These additional studies account for 1344 more VTE patients included in our analysis.

As far as ACS treatment is concerned, three meta-analysis have recently been published, which gave contrasting results. Magee et al [@pone.0044553-Magee1], consistently with our data, showed a similar rate of major bleeding in LMWH and UFH-treated patients with ACS (RR = 1), despite the fact that only one of the 7 studies included by Magee met our inclusion criteria. In contrast, Murphy et al [@pone.0044553-Murphy1], who analyzed studies comparing enoxaparin and UFH only, found an excess of major bleeding in the enoxaparin group (OR 1.25, p = 0.019). We have no explanation for the contrasting results of the analysis by Murphy et al, compared to those of the study by Magee et al and of our systematic review. The fact that Murphy et al [@pone.0044553-Murphy1] focused on studies that used enoxaparin only does not apparently account for the differences in results, because, when we restricted our analysis to studies that used enoxaparin only, we found no statistically significant differences in the incidence of major bleeding between the enoxaparin group and the UFH group ([figure S4](#pone.0044553.s004){ref-type="supplementary-material"}). The inclusion of studies that administered enoxaparin either intravenously or subcutaneously in the meta-analysis by Murphy et al might account for the different results obtained in our meta-analysis, which included those studies that administered LMWHs subcutaneously only. This concept seem to be strengthened by the most recent meta-analysis by Silvain et al [@pone.0044553-Silvain1], that enrolled RCT's and registers studies and included only patients treated with enoxeparin during percutaneous coronary interventions. While they find an important reduction in major bleeding in patients treated with intravenous Enoxeparin, the risk of bleeding using Enoxeparin by the subcutaneous route was the same as UFH.

The results of our study may have important clinical implications. Patients at high risk for thrombotic events are often also at high risk for bleeding [@pone.0044553-Loke1]; [@pone.0044553-DeEugenio1]. Iron deficiency anemia and/or hemorrhagic diathesis are common co-morbidities. In this context, the choice of the best anticoagulant treatment should be done taking into account the risk of adverse events more than the therapeutic efficacy. As a matter of fact, minimizing the bleeding risk in patients treated with anticoagulants is of utmost clinical relevance, considering that major bleeding, anemia and blood transfusion are powerful and independent predictors of morbidity and mortality in patients with VTE or ACS on treatment with antithrombotic drugs [@pone.0044553-Sabatine1]--[@pone.0044553-Jimenez1]. LMWH has the advantages of subcutaneous administration, more predictable anticoagulant response, lack of the need for laboratory monitoring and probably less risk of major bleeding in the VTE. On the other hand the lack of complete antagonization by antidotes and the long acting profile can be a disadvantage in active bleeding patients. UFH is less easy to handle, but the presence of an antidote and its brief half life could be arguments to consider in choosing the type of heparin to use in high bleeding risk patients who need anticoagulation. The choice must be based on the single patient and on the clinical and practical context, taking into account the bleeding profile of different heparins in different settings.

Limitations {#s4a}
-----------

The major limitation of our systematic review is the clinical heterogeneity between studies, especially considering all the trials together. Sources of clinical heterogeneity are several.

The primary outcome of our systematic review, major bleeding, was the secondary end-point of the original RCT that we considered in our analysis. As we included all the RCT that compared subcutaneous LMWH with UFH, we considered different clinical scenarios and consequently different study designs, in which heparins were used at different doses and with different co-therapies. However, our results should not be affected by these factors, since we considered randomized studies only. Moreover, trying to take into account clinical heterogeneity, we used a random effect model for the analysis, which is known to be more conservative.

We chose the criteria that had been used in the original studies as criteria for major bleeding and this could account for some of the heterogeneity present in our results. However, most studies considered the following major bleeding events, which are undoubtedly clinically relevant: i) the presence of intracranial or retroperitoneal haemorrhage, ii) haemorrhage that led directly to death, necessitated transfusion or led to the interruption of antithrombotic treatment, iii) a ≥2 g/dl decrease in the haemoglobin concentration.

Finally, in the arterial setting clinical and statistical heterogeneity does not allow to derive definitive conclusions; vice versa, in venous setting the sources of clinical heterogeneity are lower as confirmed by the absence of statistical heterogeneity.

In conclusion, the results of our systematic review suggest that LMWH might have a better safety profile than UFH in the treatment of VTE, while no differences between the two treatments was detected in ACS. The choice of which heparin to use to minimize bleeding risk must be based on the single patient and on the clinical and practical context, taking into account the bleeding profile of different heparins in different settings.
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